Assessing Response to Chemoradiotherapy on 18F-FDG PET Images in Non-Small Cell Lung Cancer using New Approaches of Histogram and Gray Level Co-Occurrence Matrix
Journal Title: International Journal of Cancer and Clinical Research - Year 2017, Vol 4, Issue 2
Abstract
Purpose To investigate inherent information provided by 18F-FDG PET to ameliorate shortcomings of relying on visual inspection or sole SUV measurement in treatment assessing. Patients and methods Twelve patients with newly diagnosed NSCLC and treated with combined Chemoradiotherapy (CRT) were involved in this study. We analyzed the percentage variation of gray value in every gray level or on the whole using histogram analysis algorithm which represents global intensity distribution. We also investigated texture parameters which describe local intensity-spatial distribution and were calculated by Gray Level Co-occurrence Matrix (GLCM). The parameters' variation analysis involved comparison between patient's PET scans of pretreatment and 1 month after treatment completion and correlation between characteristics variation and response degree were analyzed. The texture comparison between the same patient's lesions on one side lung and the corresponding tissue with same size, location on the other side normal lung was involved. Results The uniformity degree of gray level distribution on the whole and the maximum ratio decrease were well associated with tumor shrinkage and response degree. In that case, they were capable to differentiate tumor response to CRT. Texture parameters' variation characterizing local tumor metabolism was able to differentiate the response if these parameters were taken as indices because they showed great correlation with regional response to CRT. Conclusion We demonstrated that histogram and texture analysis methods on baseline 18F-FDG PET scans have showed more robust, discriminative in assessing response to combined CRT and may have a good application prospect in clinical practice.
Trastuzumab Emtansine in Patients with HER2-Positive Metastatic Breast Cancer: a Multicenter Japanese Retrospective Study
Introduction: Trastuzumab emtansine (T-DM1) is currently approved for the treatment of patients with HER2-positive metastatic breast cancer after failure of prior anti-HER2 therapies. However, the efficacy of T-DM1 in pa...
Clinical Utility of Serum Human Epidermal Growth Factor Receptor Type 2 Testing as a Marker of Therapeutic Response In Tissue HER2-Positive Breast Cancer Patients
Background Human Epidermal growth factor Receptor type 2 (HER2) is over expressed in 20.0-30.0% of breast cancers and is currently evaluated histopathologically. Immunohistochemistry and fluorescence in situ hybridizatio...
Angiogenesis Inhibitor Induced Thromboembolism in Cancer Patients
Therapy with Angiogenesis Inhibitors (AIs) is a newer targeted approach in treating cancers. It gained popularity in the past decade because of better outcomes and fewer side effects when compared to conventional chemoth...
Assessing Response to Chemoradiotherapy on 18F-FDG PET Images in Non-Small Cell Lung Cancer using New Approaches of Histogram and Gray Level Co-Occurrence Matrix
Purpose To investigate inherent information provided by 18F-FDG PET to ameliorate shortcomings of relying on visual inspection or sole SUV measurement in treatment assessing. Patients and methods Twelve patients with ne...
Physiological Effort in Submaximal Fitness Tests Predicts Weight Loss in Overweight and Obese Men with Prostate Cancer in a Weight Loss Trial
Background Obesity and weight gain after the diagnosis of prostate cancer are associated with an increased risk of prostate cancer recurrence and mortality; individualized plans to help prostate cancer survivors maintain...